BRPI0506865A - unusual imidazole-based hmg-coa reductase inhibitors - Google Patents

unusual imidazole-based hmg-coa reductase inhibitors

Info

Publication number
BRPI0506865A
BRPI0506865A BRPI0506865-7A BRPI0506865A BRPI0506865A BR PI0506865 A BRPI0506865 A BR PI0506865A BR PI0506865 A BRPI0506865 A BR PI0506865A BR PI0506865 A BRPI0506865 A BR PI0506865A
Authority
BR
Brazil
Prior art keywords
coa reductase
reductase inhibitors
unusual
imidazole
hmg
Prior art date
Application number
BRPI0506865-7A
Other languages
Portuguese (pt)
Inventor
Mark Richard Bush
Michael David Kaufman
Robert Michael Kennedy
Scott Douglas Larsen
Bharatkumar Kalidas Trivedi
Yuntao Song
Richard Henry Hutchings
Toni-Jo Poel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0506865A publication Critical patent/BRPI0506865A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

INIBIDORES DE HMG-COA REDUTASE INUSITADOS, BASEADOS EM IMIDAZóIS A presente invenção fornece compostos inibidores de HMG CO-A redutase, úteis como agentes hipocolesterolêmicos e hipolipidêmicos. são fornecidas também composições farmacêuticas dos compostos. Métodos para fabricar e métodos para usar os compostos também são fornecidos.UNUSED, IMMIDAZOLE BASED HMG-COA REDUCTASE INHIBITORS The present invention provides HMG CO-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic agents. Also provided are pharmaceutical compositions of the compounds. Methods for manufacturing and methods for using the compounds are also provided.

BRPI0506865-7A 2004-01-20 2005-01-10 unusual imidazole-based hmg-coa reductase inhibitors BRPI0506865A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53752504P 2004-01-20 2004-01-20
US62905804P 2004-11-18 2004-11-18
PCT/IB2005/000030 WO2005079790A1 (en) 2004-01-20 2005-01-10 Imidazole-based hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0506865A true BRPI0506865A (en) 2007-05-29

Family

ID=34890439

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506865-7A BRPI0506865A (en) 2004-01-20 2005-01-10 unusual imidazole-based hmg-coa reductase inhibitors

Country Status (6)

Country Link
EP (1) EP1727541A1 (en)
JP (1) JP2007518787A (en)
BR (1) BRPI0506865A (en)
CA (1) CA2548218A1 (en)
MX (1) MXPA06006396A (en)
WO (1) WO2005079790A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427491D0 (en) * 2004-12-16 2005-01-19 Avecia Ltd Process and compounds
WO2007051065A2 (en) * 2005-10-28 2007-05-03 Numerate, Inc. Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
WO2008022281A1 (en) 2006-08-16 2008-02-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008022286A2 (en) 2006-08-16 2008-02-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
USD721807S1 (en) 2011-09-08 2015-01-27 Ams Research Corporation Surgical indicators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808607A (en) * 1985-05-22 1989-02-28 Sandoz Pharm. Corp. Imidazole analogs of mevalonolactone and derivatives thereof for use in inhibiting cholesterol biosynthesis and lowering blood cholesterol level
DE3817808A1 (en) * 1987-07-21 1989-02-02 Bayer Ag METHOD FOR PRODUCING 2-SUBSTITUTED PYRROL
DE3739882A1 (en) * 1987-11-25 1989-06-08 Bayer Ag SUBSTITUTED HYDROXYLAMINE

Also Published As

Publication number Publication date
CA2548218A1 (en) 2005-09-01
EP1727541A1 (en) 2006-12-06
JP2007518787A (en) 2007-07-12
MXPA06006396A (en) 2006-08-23
WO2005079790A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
BRPI0506865A (en) unusual imidazole-based hmg-coa reductase inhibitors
BRPI0413468A (en) pyrrol-based hmg-coa reductase inhibitors
BRPI0509184A (en) pharmaceutical compositions
TW200634018A (en) Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and uses
DK1578733T3 (en) Process for the preparation of rosuvastatin
DK1942898T4 (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
BRPI0509926A (en) imidazoles
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
WO2008002676A3 (en) Biaryl compositions and methods for modulating a kinase cascade
WO2007103366A3 (en) Hmg co-a reductase inhibitor enhancement of bone and cartilage
TW200722427A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
EA200500201A1 (en) A NEW METHOD OF SYNTHESIS (7-METHOXY-1-NAFTYL) ACETONITRILE AND ITS APPLICATION IN THE SYNTHESIS OF AGOMELATINE
BRPI0713031B8 (en) dihydro-pyran-2-one compound, pharmaceutical composition, and use thereof
TW200738649A (en) Calcilytic compounds
EA200801413A1 (en) HETEROCYCLIC CETR INHIBITORS
DE602007005372D1 (en) TWO-TABLE TABLET FOR PREVENTING CARDIOVASCULAR EVENTS
EA200500202A1 (en) NEW METHOD OF SYNTHESIS (7-METHOXY-3,4-DIHYDRO-1-NAPHTHALINIL) ACETONITRILE AND ITS APPLICATION IN THE SYNTHESIS OF AGOMELATIN
TW200724688A (en) Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof
ATE544769T1 (en) 2-(SUBSTITUTED AMINO)-BENZOTHIAZOLESULFONAMIDE COMPOUNDS AS HIV PROTEASE INHIBITORS
BRPI0507859A (en) use of cholinesterase inhibitors
ATE496025T1 (en) MAGNESIUM SALTS OF HMG-COA REDUCTASE INHIBITORS
CR9521A (en) NEW METHOD OF TREATMENT OF HYPERLIPEDEMIA
CY1111768T1 (en) New Triglyceride Reduction Factor
SI2341054T1 (en) Process for the synthesis of HMG-CoA reductase inhibitors
UY28653A1 (en) N-RENT PIRROLES AS INHIBITORS OF HMG-COA REDUCTASA

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A,5AE 6A ANUIDADES

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.